Medtronic plc (NYSE:MDT) Shares Acquired by Cahill Financial Advisors Inc.

Cahill Financial Advisors Inc. boosted its position in Medtronic plc (NYSE:MDT) by 66.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,480 shares of the medical technology company’s stock after purchasing an additional 2,189 shares during the period. Cahill Financial Advisors Inc.’s holdings in Medtronic were worth $493,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Olstein Capital Management L.P. grew its position in shares of Medtronic by 19.2% in the third quarter. Olstein Capital Management L.P. now owns 87,000 shares of the medical technology company’s stock valued at $7,833,000 after purchasing an additional 14,000 shares during the last quarter. Manning & Napier Advisors LLC acquired a new stake in shares of Medtronic during the second quarter valued at $25,643,000. Ferguson Wellman Capital Management Inc. acquired a new stake in shares of Medtronic during the third quarter valued at $9,486,000. Harvest Portfolios Group Inc. increased its position in Medtronic by 6.5% during the 3rd quarter. Harvest Portfolios Group Inc. now owns 689,131 shares of the medical technology company’s stock worth $62,042,000 after purchasing an additional 42,112 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its stake in Medtronic by 6.3% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 368,682 shares of the medical technology company’s stock valued at $29,019,000 after purchasing an additional 21,995 shares during the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Royal Bank of Canada raised shares of Medtronic from a “sector perform” rating to an “outperform” rating and raised their price target for the stock from $98.00 to $105.00 in a research note on Thursday, October 10th. Daiwa America upgraded shares of Medtronic to a “strong-buy” rating in a research report on Friday, August 23rd. Oppenheimer boosted their price target on Medtronic from $92.00 to $94.00 and gave the company a “market perform” rating in a report on Wednesday, August 21st. UBS Group raised Medtronic from a “sell” rating to a “neutral” rating and increased their price target for the stock from $76.00 to $90.00 in a research note on Thursday, August 15th. Finally, Barclays lifted their price objective on Medtronic from $104.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $95.00.

Medtronic Trading Up 1.7 %

Shares of MDT stock opened at $86.21 on Monday. Medtronic plc has a fifty-two week low of $75.96 and a fifty-two week high of $92.68. The firm’s 50 day moving average price is $88.99 and its two-hundred day moving average price is $84.91. The stock has a market cap of $110.56 billion, a price-to-earnings ratio of 26.36, a price-to-earnings-growth ratio of 2.44 and a beta of 0.84. The company has a quick ratio of 1.39, a current ratio of 1.84 and a debt-to-equity ratio of 0.51.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.25 by $0.01. The firm had revenue of $8.40 billion during the quarter, compared to analysts’ expectations of $8.27 billion. Medtronic had a net margin of 13.00% and a return on equity of 13.79%. The firm’s revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the company earned $1.25 EPS. On average, analysts anticipate that Medtronic plc will post 5.46 EPS for the current year.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.